Nyxoah SA (NYXH): Price and Financial Metrics
GET POWR RATINGS... FREE!
NYXH Stock Price Chart Interactive Chart >
NYXH Price/Volume Stats
| Current price | $7.47 | 52-week high | $19.31 |
| Prev. close | $7.31 | 52-week low | $4.36 |
| Day low | $7.10 | Volume | 3,200 |
| Day high | $7.82 | Avg. volume | 32,695 |
| 50-day MA | $5.63 | Dividend yield | N/A |
| 200-day MA | $7.18 | Market Cap | 186.32M |
Nyxoah SA (NYXH) Company Bio
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest NYXH News From Around the Web
Below are the latest news stories about NYXOAH SA that investors may wish to consider to help them evaluate NYXH as an investment opportunity.
Nyxoah Raises $3 Million from an At-the-Market Equity OfferingINSIDE INFORMATIONREGULATED INFORMATION Nyxoah Raises $3 Million from an At-the-Market Equity Offering Mont-Saint-Guibert, Belgium – March 27, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company raised $2.8 million in gross proceeds pursuant to the Company’s $50 million at |
Nyxoah S.A. (NASDAQ:NYXH) Q4 2022 Earnings Call TranscriptNyxoah S.A. (NASDAQ:NYXH) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Thank you for standing by. And welcome to the Nyxoah Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. As a reminder, today’s call is being […] |
Nyxoah Announces a $15 Million Private Placement FinancingINSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces a $15 Million Private Placement Financing Mont-Saint-Guibert, Belgium – March 23, 2023, 9:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced a €13.35 million private placement financing from the sale of 2,047,544 new ordinary shares at a pri |
Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsCompleted all 115 implants in the DREAM U.S. pivotal study Mont-Saint-Guibert, Belgium – March 22, 2023 09:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the |
Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023 Mont-Saint-Guibert, Belgium – March 8, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and full year 2022 on Wednesday, March 2 |
NYXH Price Returns
| 1-mo | 38.33% |
| 3-mo | 49.70% |
| 6-mo | 18.57% |
| 1-year | -60.97% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 49.70% |
| 2022 | -78.30% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...